Browsing Tag
CRISPR Therapeutics
5 posts
CRISPR Therapeutics advances one-time cardiovascular strategy as CTX310 lipid reductions persist for a year
CTX310 sustains deep lipid reductions for one year as CRISPR Therapeutics expands its cardiovascular gene-editing strategy. See what comes next.
August 30, 2026
Vertex Pharmaceuticals (Nasdaq: VRTX) gains FDA approval to expand Casgevy to children as young as two
Vertex Pharmaceuticals wins FDA approval to expand Casgevy to children as young as two, reshaping sickle cell treatment economics.
July 2, 2026
How CRISPR Therapeutics’ one-and-done CTX310 therapy could transform treatment for high cholesterol and triglycerides
Find out how CRISPR Therapeutics’ CTX310 gene-editing therapy achieved profound cholesterol and triglyceride reductions — could it reshape cardiovascular care?
November 8, 2025
Biotech and Argentina-linked stocks lead April 11 US market rebound amid volatility and tariff headwinds
Discover why biotech, energy, and Argentina-linked stocks soared on April 11, 2025, as US markets rebounded despite global tariff tensions.
April 12, 2025
FDA approves Vertex and CRISPR Therapeutics’ CASGEVY for sickle cell disease
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced a significant milestone in medical science with the U.S. Food…
December 9, 2023